Bavarian Nordic A/S has announced a significant milestone with the full approval of its JYNNEOS (MVA-BN) vaccine by Singapore’s Health Sciences Authority (HSA). This approval marks an important advancement in the prevention of smallpox and mpox for adults aged 18 and older who are at high risk for these infections.
Previously available under emergency use provisions, JYNNEOS is now fully authorized in Singapore, following a pattern seen in other countries where it was similarly introduced to address mpox outbreaks. The vaccine, also known as Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN), is unique in being a non-replicating smallpox vaccine and is currently the only mpox vaccine approved in multiple regions including the US, Switzerland, and Canada, where it is marketed as IMVAMUNE. In the EU/EAA and the UK, it is available as IMVANEX.
Originally developed in collaboration with the US government, MVA-BN was designed to offer protection against smallpox, including for those with compromised immune systems who are not suitable candidates for traditional vaccines. Now, with its expanded approval, JYNNEOS aims to enhance public health responses to smallpox and mpox infections on a global scale.
